No­var­tis' Al­con unit set for Swiss/NYSE de­but on April 9; Novo's keen­ly an­tic­i­pat­ed oral GLP-1 sub­mit­ted for speedy US re­view

No­var­tis’ eye care busi­ness Al­con — be­ing spun off by the Swiss drug­mak­er — will start trad­ing on the Swiss mar­ket and NYSE on April 9. Al­con was pur­chased by for­mer No­var­tis chair­man Daniel Vasel­la for $51.6 bil­lion, but the unit’s un­der­whelm­ing per­for­mance had be­gun to weigh on No­var­tis $NVS, prompt­ing new­ly ap­proved chief Vas Narasimhan to make the de­ci­sion to of­fload it last year.

→ On Wednes­day, No­vo Nordisk $NVO sub­mit­ted a US mar­ket­ing ap­pli­ca­tion for po­ten­tial block­buster oral GLP-1, semaglu­tide, a crit­i­cal com­po­nent of the Dan­ish drug­mak­er’s long-term growth strat­e­gy. As promised, the world’s top di­a­betes drug­mak­er has used a pri­or­i­ty vouch­er to has­ten the FDA re­view process to six months, ver­sus the stan­dard ten. Sep­a­rate­ly, an NDA was sub­mit­ted for oral semaglu­tide’ use in re­duc­ing CV risk in type 2 di­a­bet­ics, but this ap­pli­ca­tion will be sub­ject to the stan­dard ten-month re­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.